Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. - Wikidata - wikimedia - TriplyDB

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.

http://www.wikidata.org/entity/Q37316293

about

Exercise programs for people with dementia Psychological treatments for depression and anxiety in dementia and mild cognitive impairment Psychological treatments for depression and anxiety in dementia and mild cognitive impairment Cognitive impairment and stroke in elderly patients Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors Assessment and management of behavioral and psychological symptoms of dementia The impact of caregivers' singing on expressions of emotion and resistance during morning care situations in persons with dementia: an intervention in dementia care.Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.Did online publishers "get it right"? Using a naturalistic search strategy to review cognitive health promotion content on internet webpages Optimal management of Alzheimer's disease patients: Clinical guidelines and family advice.An update on the diagnosis and management of dementing conditions Modulation of cholesterol in midlife affords cognitive advantage during ageing - a role for altered redox balance Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.Prevention of dementia: focus on lifestyle.Quality of dementia clinical guidelines and relevance to the care of older people with comorbidity: evidence from the literature A single blind randomized control trial on support groups for Chinese persons with mild dementia.Preventing loss of independence through exercise (PLIÉ): a pilot clinical trial in older adults with dementia.How applicable are clinical practice guidelines to elderly patients with comorbidities?Behaviour management in dementia.The "Rising Tide" of dementia in Canada: What does it mean for pharmacists and the people they care for?Psychological Treatments for Depression and Anxiety in Dementia and Mild Cognitive Impairment.Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4)Curing and caring: the work of primary care physicians with dementia patients.Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.Dementia: What pharmacists need to know.Instruments for comprehensive needs assessment in individuals with cognitive complaints, mild cognitive impairment or dementia: a systematic review.SenseCam improves memory for recent events and quality of life in a patient with memory retrieval difficulties.Vitamin E in aging, dementia, and Alzheimer's disease.Alzheimer's disease dementia guidelines for diagnostic testing: a systematic review.Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice.Shame, hope, intimacy and growth: Dementia distress and growth in families from the perspective of senior aged care professionals.Management of Behavioral and Psychological Symptoms of Dementia.Geriatric Cooperatives in Southwestern Ontario: A novel way of increasing inter-sectoral partnerships in the care of older adults with responsive behaviours.Community Pharmacists' Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD The development of quality indicators to improve psychosocial care in dementia.Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary disease and concomitant dementia: a population-based, cohort study.Cost analysis of early psychosocial intervention in Alzheimer's disease.Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease.Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.Treatment of Alzheimer's disease in Brazil: I. Cognitive disorders.

P2860

Q24186512-D61EECB0-5139-41C4-9033-23CA7C4C5772 Q24201053-B148092E-108B-405C-ADDD-026402D73295 Q24235018-47DEDC18-9BC7-42AF-92E3-A19ADCCB42D9 Q26749183-05080286-D803-4A95-B7FE-DD274CE57883 Q26997299-F2734D85-0A6E-463E-BD72-5C8F1FC2CA90 Q28088782-442AD8D9-6E52-4088-9800-02B40DFAEA65 Q30399533-DACFE0E0-B7A7-4E60-86BD-A2B8321B0C1E Q33157915-665E13F9-EA80-4D5E-B449-CD3236AE20A9 Q33805100-27D252B5-B132-455B-911C-BF04D5D2F5B3 Q33881534-AE762831-0D6F-4E89-80D4-FA9E35CE403D Q33896147-07101983-6CD9-4BD3-BC81-AD991312B5D9 Q33951174-39193052-D29F-4EA2-8ADD-594DEB234A27 Q33967781-B3983856-721A-45D6-A873-866CB43C954C Q34042415-1998AB9D-BCA4-4478-8775-0500F1D10D39 Q34090081-F6795BEE-500E-450C-83EC-B137DE8B5C8C Q34672322-566735BD-09CF-42F2-917F-DFC370FA91FC Q35074465-E432C53F-10BB-4424-BA86-869027A9F885 Q35102585-930F2BDE-75C8-43EF-9BB6-AA7D174B1521 Q35611881-A4BC82C3-8104-4968-A7ED-0C34D65FDBD8 Q35932665-D591020B-F04E-4271-9EAD-13FC678B6858 Q36188349-26D60222-D831-4873-A6A5-CBFAD0D1C157 Q36450937-6E6CACBE-87EC-4416-B370-5295F4A9D47C Q36636371-0A6390BD-36B4-4F07-B4A5-8AC169A83A4D Q37693772-B4A59D30-37F3-4424-B3E2-095F28AD8A57 Q37741796-34BEA6DF-DF37-4F85-909C-B39769BAD500 Q37891912-D5C555A2-F4E2-4D8E-8FB9-DB62AC705970 Q37937686-A7198102-334B-4948-8605-53C6B31BF869 Q37994157-DB712729-6CBE-4DB7-AE6E-95949F45543A Q38071565-2AEA8985-23B4-4972-AF2F-235A8711C3B9 Q38182842-E78807D2-FFB6-440B-B6C2-BAD9F81300EC Q38558914-DFB49247-6EAC-46A1-850D-0B6C02E8932F Q39209888-6F9200E1-C469-44E9-B874-26944E65B9BD Q40111174-3941BCA3-8326-436F-9BFC-AEFA3A26058F Q42367995-04B8F068-B145-4198-B40B-776A271D16B1 Q42632492-E66BEE3A-9930-4708-B176-5F7330DADB5A Q44047994-7FC94908-2C93-447C-9CEB-8297C16340F5 Q44140299-A53CBFCA-1CB9-479F-AA6E-0453236CC1CE Q44281582-84A54520-9BAE-465C-B941-131D0BC82169 Q47134489-DB2EE681-8D65-426A-A698-C9A845496848 Q47148252-5080DEB4-3E50-4C1E-BCC7-1C2FC443E59B

P2860

Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.

http://www.wikidata.org/entity/Q37316293

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@en

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@nl

type

label

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@en

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@nl

prefLabel

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@en

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@nl

P1433

Q37316293-3C7F65F9-3DF0-44D9-8A3F-4C31D9544660

P1476

Q37316293-59848E2B-6B64-4CF5-8B78-B5FA75B64A91

P2093

Q37316293-1EBBFD95-C234-415C-8AA0-860FF577BE22

Q37316293-28BAC2A1-A7C8-45C8-BE14-40ADECC656B3

Q37316293-2D9DC1F3-78BB-4153-8B95-7EAA3DF0B85A

Q37316293-4FE234D9-7A8B-4685-AB36-067F1FDB073F

Q37316293-87D2A92A-6D64-41CB-B3A5-70F9CF8329AA

Q37316293-A0BA17B8-3DED-42D8-B24B-FFA9583DD3A4

Q37316293-BCDE2DE2-854F-400C-9EDE-DF2B01BAAF66

Q37316293-CF880CDE-6DE4-4B88-9E41-EF1C69A3B60F

Q37316293-E2A06AC7-4598-4760-9DF9-F54CA13DA0A0

P2860

Q37316293-050574CA-51C7-438E-A260-AD10F7EE1AF6

Q37316293-07CA443E-1609-4BE3-B3BD-B329D4A27848

Q37316293-115C0A8E-FC27-492E-8FCB-6358C2FC386C

Q37316293-14B3798C-0E0C-4B26-BA05-A1300BBACF31

Q37316293-1BDE0813-D5FF-4CEB-8D64-C4C459FA48DC

Q37316293-1ED7F2AE-EC61-4DD7-BCD1-E037EEE36F0B

Q37316293-1F5E821B-02E0-4887-919B-E5A8B0D6E8E8

Q37316293-1F888389-05D0-4364-9E37-602B9ECA0DCE

Q37316293-2A1BA74F-0EDF-4161-B8F3-7D39D5DE871A

Q37316293-2CAC5762-6677-4B97-8D88-F95BBB27A1EE

P304

Q37316293-37E45A7F-C0FD-41BF-82C0-D1609FD5E7C7

P31

Q37316293-53FD3099-CE50-4CDD-8F4E-B721A0288A0D

P356

Q37316293-0FDAE2DD-99C2-474A-ABCC-9FB0C0F8A718

P407

Q37316293-32442A82-A131-4394-83E8-6346F20C1073

P433

Q37316293-8588EE45-7766-4149-B15E-C8FEE104B146

P478

Q37316293-D177A541-412D-42F4-8911-A9187C4754E3

P50

Q37316293-0EADB555-D42E-462B-8872-171051FED9D5

Q37316293-5F47AA15-BF98-45B5-B236-964477367E70

Q37316293-D9AA662E-F197-41F4-929B-AF76051A8970

Q37316293-FA21975A-16B1-4511-B0E8-C06D3EAA49A0

P577

Q37316293-0DEDB666-E59B-479A-AD9C-3AFE778C6E94

P5875

Q37316293-D6295A32-CD0F-4979-8977-FCAA39ED1BBB

P698

Q37316293-3F5689A0-5312-48A6-AA68-9FD6182F7238

P921

Q37316293-7E10097E-5379-4165-B122-D870960D7A08

Q37316293-917E0AE9-E7DD-4E3A-B478-20024AFD8476

P932

Q37316293-A5FC02B1-8FC6-4FF6-96F1-98373EEE2E62

P356

P1433

Canadian Medical Association Journal

P1476

Diagnosis and treatment of dem ...... for mild to moderate dementia.

@en

P2093

Anne Carswell

http://www.w3.org/2001/XMLSchema#string

Barry Clarke

http://www.w3.org/2001/XMLSchema#string

Carole Cohen

http://www.w3.org/2001/XMLSchema#string

Debra Morgan

http://www.w3.org/2001/XMLSchema#string

Dorothy Forbes

http://www.w3.org/2001/XMLSchema#string

John D Fisk

http://www.w3.org/2001/XMLSchema#string

Lilian Thorpe

http://www.w3.org/2001/XMLSchema#string

Malcolm Man-Son-Hing

http://www.w3.org/2001/XMLSchema#string

Peter Bailey

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

Cholinesterase inhibitors for Alzheimer's disease

Galantamine for vascular cognitive impairment

Memantine for dementia

“Mini-mental state”

Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.

The case of the missing data: methods of dealing with dropouts and other research vagaries.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials.

P304

1019-1026

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1503/CMAJ.081103

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

179

http://www.w3.org/2001/XMLSchema#string

P50

Krista L Lanctôt

Howard Chertkow

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23448809

http://www.w3.org/2001/XMLSchema#string

P698

18981443

http://www.w3.org/2001/XMLSchema#string

P921

P932

2572644

http://www.w3.org/2001/XMLSchema#string